practical recommendations for the use of sunitinib in the treatment of metastatic kidney cancer. adverse events – potential markers of its efficacy

Clicks: 239
ID: 259488
2014
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #28 of 50 articles by views in supportive care in cancer

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract

The paper deals with the specific features of sunitinib tolerance in the treatment of metastatic renal-cell carcinoma. It considers in detail the drug’s side effects that are potential biomarkers of its efficacy.

Reference Key
kharkevich2014onkourologipractical Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;G. Yu. Kharkevich;L. V. Demidov
Journal supportive care in cancer
Year 2014
DOI
DOI not found
URL
http://oncourology.abvpress.ru/index.php/oncur/article/view/91
Keywords
side effects markers of efficacymedicine

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.